Sunday, July 3

Abdala: Cuba’s anti-COVID-19 vaccine with 92% efficacy | Digital Trends Spanish

According to BioCubaFarma, the anti-COVID-19 vaccine developed by Cuba would have an efficacy of more than 92.28 percent.

According to the laboratory that produced the antigen, it would be close to becoming the first immunizer against the coronavirus created in Latin America.

In its social networks, the Island’s Center for Genetic Engineering and Biotechnology (CIGB) pointed out that with three doses the patient would obtain more than 90 percent protection against the coronavirus.

💉 Vaccine candidate #Abdala of @CIGBCuba shows an efficacy of 92.28% in its 3-dose scheme, reports @BioCubaFarma.

In video, details on how this formulation is produced: https://t.co/RQv79UUgsk pic.twitter.com/zB7LCpSQrk

& mdash; Scientific Observatory (@ObservaCiencia) June 22, 2021

Abdala is one of the five formulas against SARS-CoV-2 being investigated in Cuba and is a subunit vaccine based on the receptor-binding site (RBD) of the virus protein S.

According to those in charge, it has an application schedule of three doses administered 14 days apart.

This news was celebrated by President Miguel Díaz-Canel, who highlighted the work of the team in charge of developing the antigen and met with them to congratulate them in person together with the team of the Government’s temporary work group for the prevention and control of COVID -19.

Cuba began developing its own vaccines against SARS-CoV-2 when the first cases of infected were just registered in its territory, explaining that it was not in a position to compete with other countries for the importation of medicines.

Now, the Cuban government hopes to ask the local regulatory authority for permission for the emergency use of the vaccines and receive official approval in late June or early July.

You will then need to send the information to the World Health Organization (WHO) for eventual authorization and use abroad.

Editor’s Recommendations








es.digitaltrends.com